![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
RESULTS FROM THE PHASE 2 PEARL-I STUDY: INTERFERON-FREE REGIMENS OF ABT-450/r + ABT-267 WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 4 INFECTION
|
|
|
Reported by Jules Levin
EASL - 11 April 2014 - 49th Annual Meeting of the European Association for the Study of the Liver, London, United Kingdom
Christophe Hezode, Patrick Marcellin, Stanislas Pol, Tarek Hassanein, Katarzyna Fleischer-Stepniewska, Tolga Baykal, Tianli Wang, Sandra S. Lovell, Tami Pilot-Matias, Regis A. Vilchez
![EASL1.gif](../images/041114/041114-3/EASL1.gif)
![EASL2.gif](../images/041114/041114-3/EASL2.gif)
![EASL3.gif](../images/041114/041114-3/EASL3.gif)
![EASL4.gif](../images/041114/041114-3/EASL4.gif)
![EASL5.gif](../images/041114/041114-3/EASL5.gif)
![EASL6.gif](../images/041114/041114-3/EASL6.gif)
![EASL7.gif](../images/041114/041114-3/EASL7.gif)
![EASL8.gif](../images/041114/041114-3/EASL8.gif)
![EASL9.gif](../images/041114/041114-3/EASL9.gif)
![EASL10.gif](../images/041114/041114-3/EASL10.gif)
![EASL11.gif](../images/041114/041114-3/EASL11.gif)
![EASL12.gif](../images/041114/041114-3/EASL12.gif)
![EASL13.gif](../images/041114/041114-3/EASL13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|